ArticleWorld journal of clinical cases2019
Safety and efficacy of transjugular intrahepatic portosystemic shunt combined with palliative treatment in patients with hepatocellular carcinoma.
Article in World journal of clinical cases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 3 syntheses or guidelines pooled it, 22 citations in OpenAlex.
- Efficacy and safety of transjugular intrahepatic portosystemic shunt in patients with hepatocellular carcinoma-A systematic review and meta-analysis.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2024Pooled it
- Transjugular intrahepatic portosystemic shunt in patients with hepatocellular carcinoma: A systematic review.United European gastroenterology journal · 2023Pooled it
- Effect of transjugular intrahepatic portosystemic shunt on transarterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis.Diagnostic and interventional radiology (Ankara, Turkey) · 2021Pooled it
- Transjugular intrahepatic portosystemic shunt for esophagogastric variceal bleeding in patients with hepatocellular carcinoma and portal vein tumor thrombus.World journal of gastrointestinal surgery · 2024Article
- Does depressurization of the portal vein before liver transplantation affect the recurrence of HCC? A nested case-control study.BMC cancer · 2024Article
- Transjugular Intrahepatic Portosystemic Shunt Is Associated With Better Waitlist Management of Liver Transplant Candidates With Hepatocellular Carcinoma.Transplant international : official journal of the European Society for Organ Transplantation · 2024Article
- Risks and benefits of TIPS in HCC and other liver malignancies: a literature review.BMC gastroenterology · 2023Review
- Usefulness of antegrade foam sclerotherapy for portal hypertensive variceal bleeding.Diagnostic and interventional radiology (Ankara, Turkey) · 2023Article
- The Role of Transjugular Intrahepatic Portosystemic Shunt (TIPS) in Treating Portal Hypertension in Patients with Hepatocellular Carcinoma.Medicina (Kaunas, Lithuania) · 2023Review
- Portosystemic shunting prevents hepatocellular carcinoma in non-alcoholic fatty liver disease mouse models.PloS one · 2023Article
- TIPS improves outcomes in patients with HCC and symptomatic portal hypertension: a multi-institution experience.Cancer imaging : the official publication of the International Cancer Imaging Society · 2022Article
- Transjugular intrahepatic portosystemic shunt for the management of symptomatic malignant pseudocirrhosis.Journal of gastrointestinal oncology · 2022Article
- Feasibility and clinical value of TIPS combined with subsequent antitumor treatment in HCC patients with refractory ascites.Translational oncology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere is a close relationship between cirrhosis and hepatocellular carcinoma (HCC). Transjugular intrahepatic portosystemic shunt (TIPS) has good clinical effect in treating the complication of portal hypertension. However, because of the risk of postoperative liver failure, severe complications, and low survival rate for HCC, TIPS is contraindicated in patients with portal hypertension and liver cancer. We studied a large cohort of patients with cirrhosis and HCC who underwent TIPS for recurrent variceal bleeding and/or ascites.
aimTo assess the safety, efficacy, and survival rate in patients with HCC who underwent TIPS.
methodsGroup A comprised 217 patients with HCC and portal hypertension who underwent the TIPS procedure between 1999 and 2014. After TIPS deployment, these patients received palliative treatment for HCC. Group B comprised a cohort of 136 HCC patients with portal hypertension who did not undergo TIPS placement. Group B received palliative treatment for HCC plus medical therapy for portal hypertension. The clinical outcomes and survival rate were assessed.
resultsIn Group A, the primary technical success rate was 97.69% for TIPS placement, and no severe procedure-related complications of TIPS placement were reported. The control of variceal bleeding (VB) within 1 mo did not differ significantly between the groups (
conclusionTIPS combined with palliative treatment is safe and effective for portal hypertension in patients with HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.